The FDA is implementing real-time data monitoring and AI tools to reduce clinical trial timelines for new medications. The agency aims to give drug companies greater visibility into ongoing trials to expedite the approval process.
The Food and Drug Administration is moving to shorten drug development cycles by accessing clinical trial data as tests progress rather than waiting for completion. This shift toward real-time monitoring enables regulators to identify trends, safety concerns, and efficacy signals earlier in the process.
Artificial intelligence will play a key role in analyzing the continuous data streams, helping the FDA spot patterns that might take months or years to surface through traditional methods. The approach reduces redundant testing phases and allows for faster decision-making on drug candidates.
The initiative addresses a critical bottleneck in pharmaceutical development. Current drug approval timelines typically span years of testing before submission for regulatory review. By integrating AI-driven analytics and live data feeds, the FDA expects to maintain safety standards while cutting unnecessary delays.
The move could benefit patients awaiting treatments for serious conditions while encouraging pharmaceutical companies to invest in development. Implementation details and rollout timeline remain under development.
Z.ai has confirmed that Ox Alpha, a previously undisclosed language model, is part of its GLM-series lineup. The company plans to release the model's weights publicly.
Artificial intelligence is enabling Asian businesses to expand internationally at record speeds, according to Stripe's managing director for Southeast Asia, Greater China and South Korea.
Anthropic has released the Model Hardware Standard, a framework enabling AI agents to control physical systems like microscopes, robot arms, and quantum computing hardware. The initiative aims to standardize how AI interacts with devices while addressing emerging safety risks.
Google has launched 'Expert Intelligence,' a new feature in Gemini Notebook that pulls content from Google Play Books, allowing users to ask questions and generate AI-assisted materials based on book contents.